Want to see CANF full AI Analyst Report?
CANF Stock Chart & Stats
$4.04
-$0.06(-3.61%)
At close: 4:00 PM EST
$4.04
-$0.06(-3.61%)
Day’s Range― - ―
52-Week Range$2.56 - $21.00
Previous CloseN/A
Volume35.97K
Average Volume (3M)258.05K
Market Cap
$6.85M
Enterprise Value-$3.23
Total Cash (Recent Filing)$8.54M
Total Debt (Recent Filing)$71.00K
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 27, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding2,142,546
10 Day Avg. Volume432,468
30 Day Avg. Volume258,053
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.07
P/FCF Ratio-0.37
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$7.50Price Target Upside85.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform BreadthIndependent, peer-reviewed validation that A3AR activation affects multiple disease pathways strengthens Can‑Fite’s platform optionality. A broadly applicable mechanism supports multiple development programs, expands licensing and partnership opportunities, and reduces reliance on any single indication over the next 2–6 months and beyond.
Favorable Safety & Oral ProfileA consistent tolerability record across ~1,600 patients and oral small‑molecule delivery are durable competitive advantages. They lower clinical development risk relative to toxic or injectable therapies, improve patient adoption and make partnering/commercialization easier, supporting sustainable program progression and dealmaking.
Regulatory-aligned Phase III ProgressMeeting a protocol milestone and triggering an FDA/EMA‑agreed interim analysis for the pivotal Piclidenoson trial is a structural de‑risking event. Regulatory alignment and completed enrollment accelerate the path toward definitive efficacy readouts and potential approvals, improving partnership and commercialization prospects longer term.
Bears Say
Declining Revenue & LossesSustained small and falling revenues alongside persistent operating and net losses indicate weak commercial traction and an inability to self‑fund operations. Over months this erodes financial flexibility, forces continued reliance on external capital, and increases execution risk for late‑stage trials and commercialization plans.
Negative Cash GenerationConsistently negative operating and free cash flow create structural funding pressure. Even with partial improvements, ongoing cash burn necessitates fundraising or milestone financing, which can delay programs, divert management focus, and dilute shareholders—risks that remain material over the next several quarters.
Dilution / Governance ActionsA board proposal to substantially increase authorized share capital and grant executive options signals likely future equity issuance to fund operations. That creates durable dilution risk and potential misalignment of incentives, which can weaken shareholder returns and complicate long‑term capital planning for development programs.
Can-Fite BioPharma News
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $2.56 and its highest was $21.00 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $6.85M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Aug 27, 2026 which is in 38 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Mar 26, 2026. The company reported -$5.97 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$5.83.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Undervalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -0.33.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 2,142,546 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$5.97 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 1.858%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
CANF Stock 12 Month Forecast
Average Price Target
$7.50
▲(85.64% Upside)